The German Federal Association of Pharmacist Associations (ABDA) is calling for stricter regulation of cannabis clubs, arguing that the current framework inadequately addresses emerging health risks associated with cannabis consumption. In an interview with the “Rheinische Post” ABDA President Thomas Preis highlighted a growing body of research suggesting potential cardiovascular and metabolic complications beyond previously understood psychiatric concerns. Studies increasingly indicate a heightened risk of cardiovascular mortality and the development of Type 2 diabetes among cannabis users.
Preis also stressed the potential for dangerous drug interactions, particularly concerning widely prescribed medications. He emphasized that cannabis can impede the metabolism of numerous drugs, significantly amplifying their effects. This poses a considerable hazard for patients taking blood thinners, psychotropic medications and certain cancer treatments, a fact often overlooked in the public discussion around legalization.
The call for heightened scrutiny comes as the German government initiates a comprehensive evaluation of the recent cannabis legalization measures. A spokesperson for the Federal Ministry of Health confirmed that a preliminary report assessing the impact on cannabis-related organized crime is scheduled for release on April 1, 2026, with a more comprehensive evaluation expected by April 1, 2028. This evaluation process presents a critical window for re-examining existing regulations and addressing unforeseen consequences.
Alongside this critique, ABDA has voiced its approval of the government’s recent steps to curtail online prescriptions for medicinal cannabis. Preis lauded the requirement for direct patient-physician consultation before prescriptions are issued, noting a dramatic rise in private cannabis flower prescriptions since the partial legalization last year. He attributed this surge to online platforms that facilitate prescriptions through simplified online questionnaires, bypassing crucial personalized medical advice.
“The counseling provided in pharmacies is particularly vital when dispensing cannabis flowers” Preis stated, underscoring the substance’s considerable addiction potential and its demonstrated impact on adolescent brain development. This highlights a core concern: the potential for a rapid expansion of cannabis use, particularly amongst vulnerable populations, if robust safeguards and informed guidance are not prioritized within the current regulatory framework. The ongoing evaluation by the government now faces the pressure of incorporating these concerns to ensure public health is prioritized alongside the easing of restrictions.
